Overview

Combigan Ophthalmic Solution(Brimonidine 0.2% and Timolol 0.5%)With Latanoprost Compared With Latanoprost Monotherapy

Status:
Unknown status

Trial end date:
2006-11-01

Target enrollment:

Participant gender:

Summary

This study is to evaluate the efficacy and safety of Combigan ophthalmic solution in combination with Latanoprost when the therapy is swiched from Latanoprost monotherapy in patient with Glaucoma or ocular hypertension. Hypothesis: 1. Combigan Ophthalmic Solution provides addition IOP loweringwhen combined with Latanoprost. 2. The treatment with Combigan Ophthalmic Solution has an acceptable safety profile, as measured by ocular and systemic safety parameters.

Phase:

Phase 4

Details

Lead Sponsor:

Genovate Biotechnology Co., Ltd.,

Collaborator:

Allergan Medical

Treatments:

Brimonidine Tartrate
Brimonidine Tartrate, Timolol Maleate Drug Combination
Latanoprost
Ophthalmic Solutions
Timolol